BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
about
DNA methylation screening identifies driver epigenetic events of cancer cell survivalThe Philadelphia chromosome in leukemogenesisEvaluation of current cancer immunotherapy: hemato-oncologyKnock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cellsMolecular targets for selective killing of TRAIL-resistant leukemic cells.Regulation and Role of EZH2 in CancerExpression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Molecular Insights on Post-chemotherapy Retinoblastoma by Microarray Gene Expression AnalysisSomatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in MelanomaVaccines as consolidation therapy for myeloid leukemia.While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.Current perspectives on the therapeutic aspects of chronic myelogenous leukemia.The application of antitumor drug-targeting models on liver cancer.BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.Pattern Recognition Receptors and the Host Cell Death Molecular Machinery
P2860
Q24632287-2F677AAC-A264-43D3-9A52-15337E8D3DF4Q26745531-0A4EC15B-AE08-474E-B00C-E3A5B21A50B8Q27006179-419A9FE7-274E-4950-B46B-19781FE1AA63Q28486108-9CEC5742-DE67-49C6-8E15-9D6AF3AA6FBFQ33891400-451A56F1-2626-4ACB-9A9B-BD68D67BE793Q34043370-39E08530-1F70-4A65-B9F9-C78DD3368639Q36075245-E6BFCDB1-67D2-47E1-A7A9-BAE6E3CD8A31Q37114025-67E477D1-0879-4D75-B749-C9D978BE4F94Q37203063-2C0B6197-4D66-46D9-8C19-88E0DAB76F4AQ37218158-DC6A67FA-243C-41A7-B86E-465EF519FE5BQ37842342-0BFE6664-0249-49D8-BA31-6DB1E624BF1BQ38066406-6576DE97-34BE-4533-BBFF-332484D08CC8Q38243861-AAE1AB8E-0354-47D4-BA0A-2EF89E0CBBCFQ38972723-69528A28-7D3E-4933-B449-F9D583F9F813Q44460438-4181A6D9-DB97-4EB7-BF33-6E7B0F2AB7DEQ59136362-7CAE914F-321A-4238-9FEB-C817BACEABEA
P2860
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@en
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@nl
type
label
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@en
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@nl
prefLabel
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@en
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@nl
P2093
P2860
P356
P1433
P1476
BCR-ABL-mediated upregulation ...... ng down TRAIL in CML patients.
@en
P2093
A E B Bueno-Da-Silva
D D De Carvalho
E Abdelhay
F A Castro
G P Amarante-Mendes
J F Jacysyn
J M G Leroy
M A Zanichelli
M D Colassanti
P2860
P2888
P304
P356
10.1038/ONC.2010.409
P407
P577
2010-09-13T00:00:00Z
P5875
P6179
1041445774